title: Chemotherapy for metastatic castration-sensitive prostate cancer.
abstract: Incorporation of docetaxel into metastatic castration-sensitive prostate cancer treatment has added a new treatment option to a disease state that had previously not seen change for decades. Early attempts of a chemo-hormonal approach for castration-sensitive prostate cancer were not successful. With the demonstration of survival benefits using docetaxel in patients with metastatic castration-resistant prostate cancer, this encouraged continued research with docetaxel given earlier in the disease course. Three randomized phase III trials have defined the benefits of docetaxel in the metastatic castration-sensitive prostate cancer setting; however, there remain questions and controversies on the appropriate and optimal patient selection.
authors.affiliation: British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
authors.forename: Sunil
authors.initials: S
authors.lastname: Parimi
authors.affiliation: British Columbia Cancer Agency, Vancouver, British Columbia, Canada.|Vancouver Prostate Center, Vancouver, British Columbia, Canada.
authors.forename: Kim N
authors.initials: KN
authors.lastname: Chi
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D002369:Castration; D018450:Disease Progression; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D043823:Taxoids
keywords: castration sensitive; chemotherapy; docetaxel; metastatic; prostate cancer